Bionano Genomics Revenue Declines as Flowcell Sales Fall
Event summary
- Bionano Genomics reported Q4 2025 revenue of $8.0 million, a 3% decrease year-over-year.
- Full-year 2025 revenue totaled $28.5 million, down 7% from 2024.
- Flowcell sales decreased by 6% in Q4 2025 to 7,554 units, and by 0.2% for the full year to 30,171.
- The company installed 9 new OGM systems in Q4 2025, bringing the total installed base to 387 systems.
The big picture
Bionano's revenue decline, coupled with decreasing flowcell sales, suggests challenges in market adoption despite positive developments like the CLFS increase and growing scientific validation. The company's ability to reverse this trend hinges on demonstrating the clinical utility of OGM and expanding its application beyond hematologic malignancies, while managing costs effectively. The installed base growth, while positive, needs to translate into increased utilization to drive revenue growth.
What we're watching
- Revenue Trajectory
- Whether the anticipated revenue growth in 2026, guided between $30 and $33 million, can be achieved given the current downward trend and the impact of discontinued clinical services in the prior year.
- Flowcell Demand
- How the company will address the continued decline in flowcell sales, which is a key driver of consumables revenue and overall profitability.
- Regulatory Impact
- The extent to which the 47% increase in the Clinical Lab Fee Schedule payment determination will translate into increased adoption and revenue for OGM services in hematologic malignancies.
Related topics